期刊文献+

GLP-1受体激动剂对不同体质指数的2型糖尿患者疗效观察 被引量:8

下载PDF
导出
摘要 目的观察GLP-1受体激动剂对不同体质指数的2型糖尿病患者临床疗效及安全性。方法选取陕西省汉中市中心医院2010年6月至2011年6月门诊及住院的2型糖尿病患者30例,既往使用一种或两种口服降糖药,血糖控制不佳者,按体质指数分为两组,A组体质指数<24,B组体质指数≥24,两组均加用GLP-1受体激动剂艾塞那肽,12周后观察两组空腹血糖、餐后2h血糖、糖化血红蛋白、血脂、体质量,并记录低血糖发生次数及不良反应。结果两组患者餐后2h血糖、糖化血红蛋白、血甘油三酯较治疗前均有降低,血高密度脂蛋白较治疗前升高(P<0.05),但B组除上述指标变化更明显外,空腹血糖也有下降,且体质量下降更明显(P<0.01)。两组患者对艾塞那肽的耐受性无差别,约半数患者对10μg的剂量不能耐受。结论艾塞那肽更适用于超重或肥胖且伴血脂升高的2型糖尿患者,5μg的剂量患者耐受性好。
出处 《海南医学》 CAS 2011年第24期42-44,共3页 Hainan Medical Journal
  • 相关文献

参考文献8

  • 1Gentilella K, Bianchi C, R.ossi A, et al. Exenatide: a review from pharmacology to clinical practice [J]. Diabetes Obes Metab, 2009, 11(6): 544-556.
  • 2骆天红,郑以漫.胰升糖素样肽1对胰岛β细胞作用的研究进展[J].中华内分泌代谢杂志,2008,24(6). 被引量:38
  • 3Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glyeemic control and weight over 30 weeks in pa- tients with type 2 diabetes treated with metformin and a sulfonyl- urea [J]. Diabetes Care, 2005, 28(5): 1083-1091.
  • 4Gao Y, Yoon KH, Chuang L, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately con- trolled with metformin or mefformin and a sulphonylurea [J]. Diabe- tes Res Clin Praet, 2009, 83(1): 69-76.
  • 5Kolterman OG, Buse JB, Fineman MS,et al.Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glu- cose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2003, 88(7): 3082-3089.
  • 6兰珍,刘亚丽,巩俊卿.胰高血糖素样多肽-1对超重2型糖尿病患者的临床意义[J].武警医学院学报,2011,20(1):17-19. 被引量:1
  • 7Bcllo NT, Kemn MH, Ofeldt EM, ct al. Dose combinations of exert- din-4 and salmon calcitonin produce additive and synergistic reduc- tions in food intake in non-human primates [J]. Am J Physiol Intcgr Comp Physiol, 2010, 299(3): 945-952.
  • 8Defronzo RA, Ratner RE, Hart J, et al. Effects of excnatide(exea- din-4) on glycemic control and weight over 30 weeks in metfor- rain-treated patients with type 2 diabetes [J]. Diabetes Care, 2005, 28(5):1092-1100.

二级参考文献34

  • 1Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
  • 2Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
  • 3Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
  • 4Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
  • 5Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
  • 6Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes, 2006,55 : 1190-1196.
  • 7De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
  • 8MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.
  • 9Dyachok O, Isakov Y, Sagetorp J, et al. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting β-cells. Nature, 2006,439 : 349- 352.
  • 10Kang G, Chepumy OG, Rindler MJ, et al. A cAMP and Ca^2+ coincidence detector in support of Ca^2+ -induced Ca^2+ release in mouse pancreatic β cells. J Physiol, 2005,566 : 173-188.

共引文献37

同被引文献100

  • 1叶林秀,郭昆全,朱梅,阮华玲,孙雪,周丽荣,杨坤,邱红.胰高血糖素样肽-1类似物对2型糖尿病患者体质量及胰岛β细胞的影响[J].湖北医药学院学报,2013,32(3):213-216. 被引量:6
  • 2王川,严励,杨川,傅祖植,程桦.胰高糖素样肽1长期作用对RIN-m细胞胰岛素分泌功能的影响[J].中华内分泌代谢杂志,2006,22(1):75-76. 被引量:9
  • 3陆冉英,钟南山.内科学[M].第7版.北京:人民卫生出版社,2008:170-179.
  • 4HORTON E S, SILBERMAN C, DAVIS K L, et al. Weight loss, glycemic control, and changes in cardiovascular biomar- kers in patients with type 2 diabetes receiving incretin thera- pies or insulin in a large cohort database[J].Diabetes Care, 2010,33 (8) : 1759-1765.
  • 5GLASS L C, QU Y, LENOX S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis[J]. Curr Med Res Opin, 2008,24(3) : 639-644.
  • 6KIM M H, LEE M K. The incretins and pancreatic beta-cells: use of glucagon-like peptide-1 and glucose-dependent insulino- tropic polypeptide to cure type 2 diabetes mellitus [J]. Korean Diabetes J, 2010,34:2-9.
  • 7AHREN B, OLSSEN M L, JANSSON P A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin le- vels, and reduces glucagon levels in type 2 diabetes[J]. J Clin Endoerinol Metab, 2004,89 (5) : 2078-2084.
  • 8FEHSE F, TRAUTMANN M, HOLST J J, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes[J]. J Clin Endocrinol Metab, 2005,90 : 5991-5997.
  • 9KAHN S E, HAFFNER S M, HEISE M A, et al. Glycemic durability of rosiglitazone, metformin, or glybride monothera- py[J]. N Engl J Med, 2006,355:2427-2443.
  • 10NATHAN D M, BUSE J B, DAVIDSON M B, et al. Man- agement of hyperglycemia in type 2 diabetes: a consensus al- gorithm for the initiation and adjustment of therapy. A consen- sus statement of the American Diabetes Association and the European Association for the study of diabetes[J]. Diabetes Care, 2006,29 : 1963-1972.

引证文献8

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部